文献速递系统性红斑狼疮

系统性红斑狼疮患者血清S100A8/A9水平升高与认知障碍的相关性

Association of Elevated Serum S100A8/A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-08-11

研究纳入112例系统性红斑狼疮患者,用 adapted ACR-Neuropsychological Battery 评估认知功能,认知障碍定义为≥2个认知域受损。基线时48例(42.8%)存在认知障碍,其血清S100A8/A9水平显著高于无认知障碍者,且与多个认知域表现呈负相关;一年后S100A8/A9水平变化与认知状态变化相对应。

要点

  • 112例系统性红斑狼疮患者中48例(42.8%)基线存在认知障碍,其血清S100A8/A9水平显著更高。
  • 血清S100A8/A9水平在基线(P=0.0007,r=0.413)和一年后(P=0.0045,r=0.359)均与认知障碍相关。
  • 认知恶化组S100A8/A9水平显著升高,改善组则降低,提示水平变化与认知状态变化相对应。

核心结论

  • 在112例系统性红斑狼疮患者中,合并认知障碍者血清S100A8/A9水平升高,且与多个认知域表现呈负相关。
  • 一年内血清S100A8/A9水平变化与认知状态变化相对应,作者认为这些发现需进一步研究S100A8/A9在系统性红斑狼疮认知障碍中的作用。

研究设计与样本

  • 研究评估了112例系统性红斑狼疮患者的认知功能,采用 adapted American College of Rheumatology-Neuropsychological Battery,认知障碍定义为两个或以上认知域受损。
  • 血清S100A8/A9和基质金属蛋白酶9(MMP-9)水平用酶联免疫吸附试验测定,比较认知障碍组与非认知障碍组的血清水平,并评估基线和一年后的认知域表现。
  • 研究探索了血清水平变化与认知状态变化之间的关联。

主要发现

  • 基线时48例患者(42.8%)存在认知障碍。
  • 一年后认知功能保持稳定者占55%,改善者占31.2%,恶化者占13%。
  • 基线时认知障碍患者血清S100A8/A9水平显著更高(P=0.0007,r=0.413),一年后仍显著更高(P=0.0045,r=0.359),并与多个认知域呈负相关。
  • 认知恶化组血清S100A8/A9水平显著升高,而改善组则降低。

关键数值与推荐

  • 认知障碍定义为 adapted American College of Rheumatology-Neuropsychological Battery 评估中两个或以上认知域受损。
  • 基线时认知障碍患者血清S100A8/A9水平显著高于非认知障碍患者(P=0.0007,r=0.413)。
  • 一年时认知障碍患者血清S100A8/A9水平仍显著高于非认知障碍患者(P=0.0045,r=0.359)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出这些发现需进一步研究S100A8/A9在系统性红斑狼疮认知障碍中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cognitive impairment (CI) is common in patients with systemic lupus erythematosus (SLE). Despite its prevalence, the immune mechanisms are not well understood. We previously reported elevated serum levels of S100A8/A9 and matrix metalloproteinase 9 (MMP-9) in patients with SLE and CI. This study aims to validate those findings by examining the relationship between serum levels and CI in patients with SLE at baseline and after one year. METHODS: We assessed cognitive function in 112 patients with SLE using the adapted American College of Rheumatology-Neuropsychological Battery, defining CI as impairment in two or more domains. Serum S100A8/A9 and MMP-9 levels were measured by enzyme-linked immunosorbent assay. We compared serum levels between CI and non-CI groups, evaluated cognitive domain performance at baseline and one year, and explored associations between serum changes and cognitive status changes. RESULTS: At baseline, 48 patients (42.8%) had CI. After one year, the cognitive funtion remained stable in 55%, improved in 31.2%, and worsened in 13% of patients. Serum S100A8/A9 levels were significantly higher in CI patients at baseline (P = 0.0007, r = 0.413) and one year (P = 0.0045, r = 0.359), correlating inversely with multiple CI domains. The worsened group showed a significant increase in S100A8/A9 levels, whereas the improved group exhibited a reduction. CONCLUSION: In this large cohort of patients with well-characterized SLE, serum S100A8/A9 levels were elevated in those with CI and showed an inverse relationship with cognitive performance across multiple domains. Changes in S100A8/A9 levels corresponded with changes in cognitive status over one year. These findings warrant further investigation into the role of S100A8/A9 in CI within the context of SLE.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, et al. Association of Elevated Serum S100A8/A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2025. PMID: 40386900. doi:10.1002/acr.25575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。